Korro Bio, Inc. (NasdaqCM: KRRO)
Health Care · Biotechnology · US
$13.63
+2.64% today · -32.7% 1Y
Korro Bio, Inc. (NasdaqCM: KRRO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $195.56M and employs 57 people.
Over the last twelve months the share price has lost 32.7%, trading between 5.20 and 55.89.
Tweenvest scores Korro Bio, Inc. across four factors: quality 27/100, value 32/100. Its strongest factor is value.
KRRO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $195.56M
- Revenue (TTM)
- $2.38M
- P/E
- —
- EPS
- -8.88
- Dividend yield
- —
- Beta (5Y)
- 2.21
- 52-week high
- $55.89
- 52-week low
- $5.20
- Avg volume (3M)
- —
- Shares outstanding
- 14.73M
- Employees
- 57
- Next earnings
- —
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
- ISIN
- US5009461089
- Founded
- 2018
- Listed since
- Oct 3, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.93 | +0.53% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.08 | +0.28% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $147.46 | +0.49% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $553.68 | +1.11% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $836.15 | +0.92% |
| argenx SEENXTBR: ARGX | $63.06B | €877.40 | +1.53% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $156.39 | +12.60% |
Figures last refreshed Aug 18, 2026.